INmune Bio reports the results of a double-blinded, randomized, placebo-controlled pivotal trial, known as “MissionEB,” investigating CORDStrom for treatment of RDEB in pediatric patients, which evidence a favorable benefit-risk profile in support of the intended applications for marketing authorization.